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Since publication of this manuscript, it was recognised that there is an error in [Figure 3D and E](#fig3){ref-type="fig"} of the results. The correct figure is presented here.

The sample labels for 'anti-Notch 2' and 'NC' were incorrectly placed for the EC 9706 and Eca 109 cell lines in [Figure 3D and E](#fig3){ref-type="fig"}, and the protein 'vimentin' was incorrectly labelled as 'N-Cadherin' in [Figure 3D](#fig3){ref-type="fig"}. The results are correctly described in the main text of the manuscript, and the incorrect figure had no effect on the overall study conclusions.
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![**Notch2 promotes EMT of ESCC.** (**A**) shRNA transfection of Notch2 could inhibit its expression. (**B**, **C**) shRNA-Notch2 inhibited invasion ability of ESCC. (**D**, **E**) shRNA-Notch2 regulated EMT markers of ESCC. \*\**P*\<0.01; \*\*\**P*\<0.001.](bjc2017471f3){#fig3}
